4-(4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl)butanoic acid | 129725-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl)butanoic acid
• 英文别名: 4-[4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl]butanoic acid；4-(4-ethoxycarbonyl-5-methyl-1H-pyrrol-3-yl)butanoic acid
• CAS: 129725-05-9
• 化学式: C₁₂H₁₇NO₄
• 分子量: 239.271
• InChiKey: PCRIVVFUPLBPSI-UHFFFAOYSA-N

物化性质

• 沸点：
  455.6±45.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl)butanoic acid 在 吡啶 、 四磷十氧化物 、 四氯化钛 、 lithium hydroxide 作用下， 反应 84.0h， 生成 2-methyl-7-[1,2-dihydro-2-oxo-3H-indol-(Z)-3-ylidene]-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors

  摘要：

  A novel series of 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives targeting VEGFR-2, PDGFR-beta and c-Kit kinases were designed and synthesized. The molecular design was based on the SAR features of indolin-2-ones as kinase inhibitors. SAR study of the series allowed us to identify compounds possessing more potent inhibitory activities against the three kinases than sunitinb with IC50 values in the low nanomolar range in vitro. Additionally, some compounds also showed favorable antiproliferative activities against a panel of cancer cell lines (BXPC-3, T24, BGC, HEPG2 and HT29). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.037
• 作为产物：
  描述：

  6-amino-5-oxohexanoic acid hydrochloride 、 乙酰乙酸乙酯 以 水 为溶剂， 反应 0.5h， 以71%的产率得到4-(4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-3-yl)butanoic acid
  参考文献：
  名称：

  3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof

  摘要：

  公式（I）的3-吡咯[ b ]环己烯-2-二氢吲哚酮衍生物或其药用盐及其用途。用于制备上述化合物的公式（II）的中间体。生物测定表明，上述化合物及其药用盐可以调节蛋白激酶（PKs）的活性，抑制酪氨酸激酶（PTKs）的活性，并抑制多种类型的肿瘤细胞。

  公开号：

  US20100160318A1

文献信息

• [EN] TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRROLO TRICYCLIQUES, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION À TITRE D'INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012101032A1

  公开（公告）日：2012-08-02

  The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的三环吡咯衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用途。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof
  申请人：Tang Feng

  公开号：US20100160318A1

  公开（公告）日：2010-06-24

  3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.

  公式（I）的3-吡咯[ b ]环己烯-2-二氢吲哚酮衍生物或其药用盐及其用途。用于制备上述化合物的公式（II）的中间体。生物测定表明，上述化合物及其药用盐可以调节蛋白激酶（PKs）的活性，抑制酪氨酸激酶（PTKs）的活性，并抑制多种类型的肿瘤细胞。
• 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof
  申请人：Jiangsu Simcere Pharmaceutical R&D Co. Ltd.

  公开号：US08084621B2

  公开（公告）日：2011-12-27

  3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.

  式(I)的3-吡咯[b]环己基-2-二氢吲哚酮衍生物或其药学上可接受的盐，以及它们的用途。式(II)的中间体用于制备上述化合物。生物测定表明，上述化合物及其药学上可接受的盐可以调节蛋白激酶(PKs)的活性，抑制酪氨酸激酶(PTKs)的活性，并抑制许多种肿瘤细胞。
• TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Caldarelli Marina

  公开号：US20130296305A1

  公开（公告）日：2013-11-07

  The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的三环吡咯衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面有用。本发明还提供了制备这些化合物的方法，包括这些化合物的制药组合物以及利用这些化合物或含有它们的制药组合物治疗疾病的方法。
• Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Caldarelli Marina

  公开号：US08975267B2

  公开（公告）日：2015-03-10

  The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的三环吡咯衍生物，其调节蛋白激酶的活性，因此在治疗由失调蛋白激酶活性引起的疾病方面有用。本发明还提供了制备这些化合物的方法，包含这些化合物的药物组合物以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。